Soligenix: Late-Stage Biopharma Addressing a $2 Billion Opportunity

1 year ago
2

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company specializing in developing and commercializing products to treat rare diseases with unmet medical needs. The Company's primary focus is on its Specialized BioTherapeutics business segment, which is responsible for the development of HyBryteâ„¢, a novel photodynamic therapy that uses safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). The Company has successfully completed a Phase 3 study for HyBryteâ„¢ and is now negotiating a confirmatory Phase 3 pivotal study design with the US Food & Drug Administration, while also evaluating/pursuing potential HyBryteâ„¢ marketing approval ex-U.S. with the successfully completed Phase 3 study. Visit SNGXinfo.com to learn more.

Loading comments...